Table 2. Stratification of glaucoma by ethnicity, age, and gender for predictive assessment with and without using metabolite data.
| Stratification | Sample size | Glaucoma cases | No Metabolites (AUC) | Metabolites (AUC) | p-value |
|---|---|---|---|---|---|
| Ethnicity | |||||
| White | 110,243 | 4,331 | 0.675 | 0.686 | <0.001 |
| Asian | 3,104 | 127 | 0.780 | 0.768 | 0.062 |
| Black | 2,358 | 130 | 0.704 | 0.706 | 0.52 |
| Age | |||||
| <55 years | 43,648 | 788 | 0.576 | 0.566 | 0.52 |
| ≥55 years | 74,050 | 3,870 | 0.569 | 0.596 | 0.002 |
| Gender | |||||
| Female | 62,708 | 2,165 | 0.689 | 0.696 | 0.25 |
| Male | 54,990 | 2,493 | 0.659 | 0.673 | 0.002 |
The area under the curve (AUC) of the receiver operating characteristic (ROC) curve was calculated for each demographic stratification to evaluate the predictive performance of models both with and without metabolite data. Differences in model AUC were tested using the DeLong test, and p-values were reported. For models excluding metabolite data, the predictors include as appropriate, age (years), sex, genetic ancestry, season, time of day of specimen collection, fasting time (hours), smoking status (never, past, and current smoker), alcohol intake (g/week), caffeine intake (mg/day), physical activity (metabolic equivalent of task [MET], hours/week), body mass index (kg/m2), average systolic blood pressure (mm Hg), history of diabetes, HbA1c (mmol/mol), history of coronary artery disease, systemic beta-blocker use, oral steroid use, and spherical equivalent refractive error (diopters). Models including metabolite data incorporated the same predictors with the addition of the 168 metabolite measurements.